UBS analyst Trung Huynh upgraded Amgen (AMGN) to Buy from Neutral.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- M&A News: Amgen Stock (AMGN) Brightens after $840M Capture of British Cancer-Fighting Biotech Dark Blue
- Amgen acquires Dark Blue Therapeutics in deal valued at up to $840M
- MSFT, CRM, ORCL: Why Evercore Names These 3 Software Stocks as ‘Top Picks for 2026’
- Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease